...Hello, everyone, and welcome to the Biovica Q1 interim report. Today, it will be me, Anders Rylander; together with my CFO, Anders Moren; and Hector Tamburini, Head of US operations; and Henrik Winther, Head of Business Development and pharma services will be presenting. And the agenda will be a short introduction about the company. We'll focus on the Q1 highlights. Anders will go into the financials. Hector will give an update about the US progress, and Henrik will do the same for pharma services. And at the end, there will be a summary, and we'll open up for a Q&A session. The way the Q&A session will work is that, first, we will let our financial analysts in, which you see here on the screen, Johan from Redeye and we have Pareto, and Luisa from Kempen also. (Event Instructions) So if I start with a very short introduction of Biovica, what we do. We have our product, DiviTum, that measures cell proliferation. Cell proliferation of course, is essential for us humans, and it's also a hallmark...
